Loading...
Market
What will be the first major research milestone achieved by Project Transfidelity by December 31, 2024?
2
Resolution / Starting Odds
Enhanced cognitive function in animal models • 25%
Identification of a new drug candidate • 25%
Development of a new diagnostic tool • 25%
Other • 25%
Official announcements from Project Transfidelity or affiliated DAOs (VitaDAO, CerebrumDAO, BeakerDAO)
Story
Project Transfidelity Raises 76 ETH, First IPT Funded for Alzheimer's Research
Aug 29, 2024, 10:01 AM
Project Transfidelity, an initiative focused on Alzheimer's research, has successfully closed its funding round on Catalyst, raising a total of 76 ETH. The project, which aims to enhance brain performance at any age, was collaboratively funded by three decentralized autonomous organizations (DAOs): VitaDAO, CerebrumDAO, and BeakerDAO. The funding effort was driven by the personal experiences of researchers like Dr. Rashid Akbergenov, who was motivated by the impact of neurodegenerative diseases on his colleagues and friends. The project has been described as a groundbreaking step in democratizing early-stage research funding through the use of IP tokens. It marks the first IPT funded collaboratively by these DAOs.
View original story
Similar markets
Yes • 50%
No • 50%
Launches beta version • 25%
Launches full version • 25%
Secures 100+ clients • 25%
Other • 25%
New AI Algorithm • 25%
New Bioscience Discovery • 25%
New Laboratory Technique • 25%
Other • 25%
Surpasses GPT-4 in reasoning tasks • 25%
Successfully integrated into existing OpenAI products • 25%
Demonstrates human-like reasoning in a public demo • 25%
Other milestone • 25%
Discrepancy in reserves • 25%
Compliance with reserves • 25%
Technical issues • 25%
Other • 25%
Other • 25%
Improved accuracy over 99% • 25%
Reduced size and invasiveness • 25%
Extended functionality beyond speech • 25%
Gram-positive bacteria • 25%
Gram-negative bacteria • 25%
Fungi • 25%
Other • 25%
FDA approval for commercial use • 25%
Integration with another major tech device • 25%
Partnership with a major tech company • 25%
Clinical trials expansion • 25%
Yes • 50%
No • 50%
Level 2 • 25%
Level 3 • 25%
Level 4 • 25%
Level 5 • 25%
Surpasses human performance in a specific task • 25%
Achieves a breakthrough in natural language processing • 25%
Reaches a new level of general AI • 25%
Other • 25%
Safety and Risk Mitigation • 25%
Efficiency and Performance • 25%
Ethical Considerations • 25%
Public Health Impact • 25%